ClinicalTrials.gg
Not yet recruitingNCT07947589Updated Nov 19, 2026

ToeFX Light Therapy for Chronic Venous Leg Ulcers

An interventional study of Non-thermal photodynamic therapy in Venous Leg Ulcer (VLU), Venous Leg Ulcers (VLUs) and Wound Closure, sponsored by Dr. Ahmed Kayssi. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Dr. Ahmed Kayssi · Not applicable, Interventional, and Device feasibility

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 22 studies in Varicose Ulcer with a site in Canada — 2 open to participants now, 2 under way, 1 of them phase 3. Varicose Ulcer · Canada.

Planned enrollment
14th of 18
20 · median 101
Started
2026
the only one that year
No phase
10 of 22
1 open now
Registered
22nd of 22
by date
Lead sponsor
1 of 22
Dr. Ahmed Kayssi

Among the 22 studies in Varicose Ulcer with a site in Canada, this one is the 14th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2026, is one of 10 with no phase, and was the 22nd registered.

Varicose Ulcer

371 studies on the registry are indexed under Varicose Ulcer; 74 are open to participants now.

Browse Varicose Ulcer studies →

Open to participants now

2 of the 22 studies in Varicose Ulcer with a site in Canada are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 50 Varicose Ulcer studies recruiting now, 40 (80%) set no upper age limit and 5 (10%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Varicose Ulcer with a site in Canada, or all of them as a file.
02

Study summary

Chronic venous leg ulcers can be painful and prone to infection. They can significantly limit a patient's function, mobility and quality of life.

A major contributor to delayed ulcer healing is persistent bacteria. Treatments that can penetrate the bacteria's protective outer shield to kill and clear the bacteria are important for helping ulcers heal more quickly.

The purpose of this pilot study is to test a topical study treatment (called ClearToe Serum®) plus two types of light (red and blue-purple light) in the treatment of chronic venous ulcers.

This is an open-label single-arm pilot study. All participants will receive the test treatment as well as standard or care treatment for their chronic venous ulcer. Participants will receive study treatments one per week for up to 12 weeks, or until their ulcer is healed.

The main objectives are to assess adherence to the one-per-week study treatments, and to note any study device-related, study treatment-related, or serious adverse events, or adverse events that lead to stopping study treatment.

Read the detailed description

Chronic venous leg ulcers (VLUs) are a common and costly. They affect about 1% adults and are a significant burden to patients and the healthcare system. VLUs are often painful, malodorous, and prone to infection. They can have a big impact a patient's function, mobility, and quality of life. Standard of care (SOC) treatment, meaning the usual treatment, includes compression therapy, regular wound care (removing dead tissue, cleaning and dressing the wound), and infection management. Even with SOC treatment, about half of VLUs persist for months or years.

A major contributor to delayed healing is persistent bacterial infection, including bacteria that produce a biofilm, a protective covering resistant to many topical and systemic antibiotics. Strategies that can penetrate the biofilm to reduce local bacterial infection without contributing to antibiotic resistance are of particular interest in chronic wound management.

ToeFX has developed a non-thermal photodynamic therapy (PDT) platform that combines a methylene-blue-based photosensitizer (ClearToe® serum) with 660 nm light irradiation. Upon activation by light of the appropriate wavelength, the photosensitizer generates reactive oxygen species that are toxic to a broad range of bacteria but harmless for host tissue. This mechanism of photodynamic disinfection is well established in other clinical contexts, and the ToeFX platform is currently approved/registered for other indications. The ToeFX ClearToe® system is approved by Health Canada for the treatment of onychomycosis (toenail fungus). Its potential to reduce local bioburden and support a more favourable wound-healing environment has not yet been formally evaluated in venous leg ulcers.

This pilot study is intended to evaluate the feasibility (treatment adherence) and safety of ToeFX photodynamic therapy as an adjunct to SOC in a defined population of patients with chronic venous leg ulcers, while collecting preliminary clinical, wound-healing, and patient-reported outcome data to inform the design of a future, larger controlled trial.

03

Conditions studied

  • Venous Leg Ulcer (VLU)
  • Venous Leg Ulcers (VLUs)
  • Wound Closure
  • Wound Care

Keywords

  • venous
  • leg
  • ulcer
  • wound
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Able to attend weekly visits for up to 12 weeks
  • Chronic venous leg ulcer (CEAP C6) of the lower extremity
  • Ulcer duration of 4 weeks or more
  • Ulcer size between 1 cm² and 20 cm² at baseline
  • Receiving standard-of-care compression therapy, or eligible to initiate it
  • Able to provide and comply with study procedures

Exclusion criteria

Exclusion Criteria:

  • Wound location or anatomy not compatible with the ToeFX photodynamic therapy device
  • Systemic infection (e.g., fever, sepsis, spreading cellulitis) or wound requiring systemic antibiotics
  • Necrotic tissue over 25% of the wound bed, exposed bone or tendon, deep abscess, osteomyelitis or gangrene
  • Severe ischemia (ABI below 0.5) or poorly controlled diabetes ( above 10%)
  • Heavy exudate requiring negative-pressure wound therapy
  • Known photosensitivity or allergy to methylene blue or light-based therapies
  • therapy, radiation or chemotherapy within the past 3 months, or active
  • Pregnancy or lactation
  • Known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
  • Participation in another interventional study within 30 days of screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    ToeFX Treatment

    Weekly ToeFX treatment of venous leg ulcer up to 12 weeks or wound closure

    Device: Non-thermal photodynamic therapy

Interventions

  • DeviceNon-thermal photodynamic therapy

    Non-thermal photodynamic therapy platform that combines a methylene-blue-based photosensitizer ( ClearToe® serum) with 660 nm light irradiation

    Also known as: ToeFX, ClearToe Serum

06

What researchers measure

Primary outcomes

  1. Treatment adherence

    Percentage of planned ToeFX treatment sessions completed per participant, and reasons for missed or discontinued sessions

    Time frame: Baseline through Visit 12/ end of treatment (up to 12 weeks)

  2. Safety: Adverse Events

    Incidence and severity of adverse events (AEs), serious adverse events (SAEs), device-related AEs, treatment-related AEs, and study discontinuations due to AEs

    Time frame: Baseline through Healing Confirmation Visit (up to 14 weeks)

Secondary outcomes

  1. Percent Change in Wound Area From Baseline

    Percent change in wound area (cm²) from baseline

    Time frame: Baseline, week 4, week 8, and week 12

  2. Complete wound epithelialization

    Proportion of participants achieving complete epithelialization by Week 12, as assessed by clinician

    Time frame: 12 weeks

  3. Time to complete wound healing

    Time (days) from baseline to complete epithelialization

    Time frame: 12 weeks

  4. Change in Bates-Jensen Wound Assessment Tool (BWAT) score

    Change in wound bed characteristics measured using the BWAT

    Time frame: Baseline to 12 weeks/ end of treatment

  5. Change in pain score

    Change in pain score (0-10 Numeric Rating Scale)

    Time frame: Baseline to 12 weeks/ end of treatment

  6. Change in health-related quality of life

    Change in EQ-5D-5L score

    Time frame: 12 weeks/ end of treatment

  7. Patient satisfaction

    Patient-reported satisfaction with treatment measured by study-specific patient satisfaction questionnaire

    Time frame: 12 weeks/ end of treatment

  8. Clinician feasibility

    Qualitative and operational observations on feasibility of integrating PDF into routine wound care workflow

    Time frame: 14 weeks or earlier if wound healing

  9. Absolute Change in Wound Area From Baseline

    Absolute change in wound area (cm²) from baseline

    Time frame: Baseline, week 4, week 8, and week 12

07

Study locations

1 site
  • East Toronto Vascular Clinic
    Toronto, Ontario M4L 3Y3, Canada
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — This is a small single-centre pilot study. Individual participant data will not be shared because of participant privacy considerations and the terms of the clinical trial agreement with the study funder. Data are de-identified using study IDs and stored with restricted access. Aggregate results will be published.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Oct 2027, 11 months later.

Of 67 non-industry interventional studies with no phase under Varicose Ulcer, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 65. This study's planned 11 months is below that.

Counting every sponsor, half of 134 studies reached it within 28 months; a quarter within 13 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
Nov 15, 2026
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947589
Lead sponsor
Dr. Ahmed Kayssi
Responsible party
Dr. Ahmed Kayssi (MD DrPH CWSP FRCSC FACS, Sunnybrook Health Sciences Centre) — Sponsor-investigator
First posted
Nov 19, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Ahmed Kayssi, MD MSc FRCSC
Contact
ahmed.kayssi@sunnybrook.ca
(416) 691-2030
Ahmed Kayssi, MD MSc FRCSC
principal investigator · East Toronto Vascular Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion